Full-Time
Quality Engineer Software
Posted on 9/10/2026
Philips
Healthcare technology for diagnosis, care, wellness
No salary listed
Bengaluru, Karnataka, India
Hybrid
At least three days in the office per week.
Bachelor's
 Biology & Biotech (1) |
|---|
- A bachelor's degree in Computer Science, Computer Applications, or equivalent vocational education.
- Five to seven years of experience in Software Quality Engineering.
- Working knowledge of relevant global regulations, requirements, and standards.
- Working knowledge of software quality engineering practices, regulatory compliance, and quality management system processes.
- Participate in developing and maintaining comprehensive software quality documentation, including Software Requirement Specifications, throughout the software lifecycle.
- Assess software designs by reviewing test and performance data against quality, safety, and regulatory standards, and address quality engineering deficiencies.
- Conduct root cause analysis for software quality issues and resolve deficiencies to improve software design processes.
- Guide validation of software design inputs including usability, reliability, performance, localizability, safety, privacy, and cost.
- Oversee execution of software quality plans and associated risk management activities throughout the software lifecycle.
- Use post-market analytics and statistics to monitor software performance, provide feedback to manufacturing, suppliers, and design teams, and initiate corrective or field actions when required.
- Participate in developing Software Quality Plans covering the software lifecycle from design through post-market.
- Ensure software quality activities and design processes comply with applicable regulatory requirements.
- Provide guidance to meet schedules, resolve technical problems, and manage performance requirements, including mentoring on quality engineering practices, regulatory compliance, and quality management system processes.
- Report key software quality metrics aligned with business objectives and regulatory expectations to relevant stakeholders.
- ISTQB certification.
- Design Quality Management.
- Data Analysis and Interpretation.
- Design for Quality.
- Root Cause Analysis.
- CAPA methodologies.
- Regulatory requirements.
- Privacy, safety, and security risk assessment.
- Technical documentation.
- Continuous improvement.
- Software Development Life Cycle.
- Product quality and reliability.
- Defect management.
- Design Verification Planning.
- Design Validation Planning.
- Product Test Design.
Philips develops health technology across professional medical devices, connected care, and consumer health products. Its offerings include diagnostic imaging and image-guided therapy, patient monitoring and clinical informatics, and everyday wellness products like oral and personal care. The company increasingly delivers integrated solutions through a Healthcare-as-a-Service subscription model and long-term partnerships with hospitals and health systems. Its aim is to improve people’s health and well-being by making advanced health technology easier to access and integrate into care.
Company Size
N/A
Company Stage
IPO
Headquarters
Andover, Minnesota
Founded
1891
Simplify's Take
What believers are saying
- Q2 2026 sales rose 4%, and Philips raised 2026 margin guidance.
- June 2026 IntelliVue 6000 targets rural hospitals and ASCs with lower-cost enterprise monitoring.
- August 2026 monitoring partnerships with Blue Spark, Caretaker, and Cuviva expand hospital-at-home reach.
What critics are saying
- FDA consent decree still restricts Philips Respironics U.S. sleep-device manufacturing in 2026.
- August 2026 Brilliance CT recall shows unresolved quality control failures across imaging hardware.
- July 2026 China pressure and delayed U.S. orders hit bookings; margin depends on refunds.
What makes Philips unique
- Philips spans imaging, monitoring, and consumer health, reducing dependence on any single procedure area.
- Its open monitoring ecosystem links hospital and home devices through partner integrations and software.
- Philips sells enterprise-grade workflows, not standalone hardware, through diagnostics and connected-care platforms.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Health Savings Account/Flexible Spending Account
Company News
The global remote patient monitoring market is expected to grow from $67.3 billion in 2026 to $117.9 billion by 2033, registering a CAGR of 8.3%. Growth is driven by rising chronic disease prevalence, expanding telehealth services and increasing demand for home-based healthcare solutions. Devices and hardware account for nearly 38% of market share, led by connected blood pressure monitors, glucometers and wearable health trackers. North America holds approximately 41% of the global market, supported by strong digital healthcare infrastructure and favourable reimbursement policies. Asia Pacific is emerging as the fastest-growing region, driven by healthcare digitisation, telemedicine expansion and rising smartphone penetration. Leading players include Philips Healthcare, Medtronic, GE HealthCare and Abbott Laboratories, focusing on AI integration and cloud connectivity to enhance remote care delivery.
<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US, subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024. The company’s previously announced 2023-2025 financial outlook remains unchanged, already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more
Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.
In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.
February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.